Plus Therapeutics (PSTV) Q4 2024 earnings summary

Executive summary

• Closed $15M underwritten equity financing in March 2024, extending cash runway into 2026 and regaining Nasdaq compliance.

• Advanced REYOBIQ/Rheobic with positive Phase 1 data in glioblastoma and leptomeningeal metastases, including FDA Orphan Drug Designation for LM in lung cancer.

• CNSide diagnostic platform demonstrated clinical utility and is on track for full commercial launch in 2025.

• Strengthened leadership with key hires and appointments to support clinical, regulatory, and commercial operations.

• Received $2M in accelerated grant proceeds from CPRIT, with further grant funding anticipated.

Financial highlights

• Cash and investments at year-end 2024 were $3.6M, down from $8.6M at year-end 2023.

• 2024 grant revenue was $5.8M, up from $4.9M in 2023; 2025 grant revenue expected at $6–8M, with $2M already received.

• Operating loss for 2024 was $14.7M, compared to $13.3M in 2023, mainly due to increased R&D and RESPECT-LM trial spending.

• Net loss for 2024 was $13M ($1.95/share), compared to $13.3M ($4.24/share) in 2023.

• Weighted average shares outstanding increased to 6.6M in 2024 from 3.1M in 2023.

Outlook and guidance

• Cash runway fully funded into mid-2026, supported by recent equity raise and grant inflows.

• Full commercial launch of CNSide planned for 2025, with transition to revenue generation.

• 2025 milestones include completion of ReSPECT-GBM and RESPECT-LM trial enrollments, IND approval for pediatric brain cancer trial, and multiple data presentations at major conferences.

• Financial guidance for CNSide to be provided later in 2025 as visibility improves.